版本:
中国

Johnson & Johnson expects to complete of Actelion offer on June 16

ZURICH, June 9 Johnson & Johnson said Friday's approval of its proposed acquisition of Swiss biotech company Actelion by the European Commission meant all regulatory approvals required to complete the $30 billion deal have been received.

The U.S. company said it expects settlement of the all-cash public tender offer by its Swiss subsidiary, Janssen Holding, on June 16.

EU antitrust regulators approved on Friday Johnson & Johnson's planned purchase of Actelion subject to conditions intended to ensure clinical development of insomnia drugs were unaffected. (Reporting by John Revill; editing by Brenna Hughes Neghaiwi)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐